Mumbai: The shares of pharmaceutical companies recorded a decline on Thursday. The pharma stocks fell as there are growing concerns over the upcoming US tariff policy. According to a Bloomberg report, the US administration is considering imposing tariffs of up to 100% on imported branded and patented drugs. Notably, US President Donald Trump has hinted at levying tariffs of 100% to 200% on such products. Trump wants the pharmaceutical companies to produce in the US and reduce drug prices in the country.
Some major pharmaceutical giants, such as Pfizer Inc. and Eli Lilly and Company, have reached agreements with the US government that could provide them with relief from tariff for three years. However, several firms are yet to reach any agreement with the US government. The uncertainty over tariffs have made investors cautious, leading to a decline in pharmaceutical sector stocks.
At the time of writing this article, the pharma benchmark Nifty Pharma declined 1.28 per cent to 21,728.85. The stock of companies such as Divi’s Labs, Zydus, Sun Pharma, Lupin, Cipla, recorded drop intraday.
On April 1, 2026, (the first day of new financial year 2026-27), Nifty Pharma settled at 22,011.60. Today, Thursday, it opened with a gap down at 21,689.95. Intraday, the index went down by nearly 4 percent as compared to Wednesday’s closing price.
Sun Pharmaceutical Industries’ stock was trading with 2.38 per cent losses at Rs 1,687.30 apiece.
Divi’s Laboratories’ share price fell by 1.36 percent to 5,826.
Torrent Pharmaceuticals shares went south as it declined over 3 per cent to 3,988.
Other companies such as Lupin, Cipla, Zydus, Manking Pharma, and Aurobindo Pharma also witnessed their share price going down. However, Dr. Reddy’s Labs stock traded with gains.
(Disclaimer: This article is only meant to provide information. News9 does not recommend buying or selling shares or subscriptions of any IPO, Mutual Funds, precious metals, commodity, REITs, InvITs and any form of alternative investment instruments and crypto assets.)